China Commerce Minister Meets Global Pharma Leaders

In a move to bolster international business relations, the Commerce Minister of China, Wang Wentao, convened a high-level meeting on Sunday with prominent leaders from the global pharmaceutical sector. The discussions focused on enhancing the operating environment for foreign drug manufacturers as the nation seeks to revitalize its foreign direct investment levels. The meeting included Stephen Ubl, President and CEO of the Pharmaceutical Research and Manufacturers of America, representing the pharmaceutical industry of the United States. Executives from major multinational corporations were also in attendance, including representatives from NOVARTIS AG-REG, AstraZeneca PLC, Roche Group, Boehringer Ingelheim, and Organon & Co.. During the session, Minister Wang highlighted the strategic importance of the sector, noting that the 15th Five-Year Plan identifies biopharmaceuticals as an emerging pillar industry. He acknowledged the significant contributions of these firms to the local economy. > Wang said multinational pharmaceutical companies have established China as a global R&D base and noted that Chinas 15th Five-Year Plan lists biopharmaceuticals as an emerging pillar industry. To address concerns from the international business community, the minister pledged that the government would take concrete steps to improve the regulatory landscape. This includes strengthening intellectual property protections and increasing the transparency of policy implementation to create more predictable opportunities for expansion. > The minister said China will strengthen intellectual property protection and improve policy transparency, providing new opportunities for multinational pharmaceutical companies to expand in China. This outreach follows a broader initiative launched in December to expand the range of industries eligible for government incentives, such as preferential land use and tax breaks, as Beijing works to reverse a recent decline in foreign investment.